Citigroup Inc. Boosts Stock Position in Twist Bioscience Corporation $TWST

Key Points

• Citigroup Inc. increased its stake in Twist Bioscience Corporation by 124.1% in the first quarter, owning 206,461 shares valued at $8.11 million.
• Several other major investors, including ARK Investment Management LLC and Vanguard Group Inc., also expanded their positions in Twist Bioscience during the same period.
• The stock has a consensus rating of "Moderate Buy" from analysts, with a price target ranging from $33.00 to $55.00, reflecting varying investor sentiments.

Citigroup Inc. raised its stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 124.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 206,461 shares of the company's stock after purchasing an additional 114,338 shares during the period. Citigroup Inc. owned 0.34% of Twist Bioscience worth $8,106,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. ARK Investment Management LLC increased its stake in Twist Bioscience by 11.5% in the first quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock valued at $245,045,000 after purchasing an additional 645,730 shares during the last quarter. Vanguard Group Inc. increased its stake in Twist Bioscience by 1.0% in the first quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock valued at $230,356,000 after purchasing an additional 60,276 shares during the last quarter. First Light Asset Management LLC purchased a new position in Twist Bioscience in the fourth quarter valued at approximately $56,984,000. Northern Trust Corp increased its stake in Twist Bioscience by 9.0% in the fourth quarter. Northern Trust Corp now owns 627,649 shares of the company's stock valued at $29,167,000 after purchasing an additional 51,926 shares during the last quarter. Finally, New York State Common Retirement Fund increased its stake in Twist Bioscience by 2.4% in the first quarter. New York State Common Retirement Fund now owns 452,750 shares of the company's stock valued at $17,775,000 after purchasing an additional 10,761 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on TWST shares. Evercore ISI set a $46.00 target price on shares of Twist Bioscience in a research report on Monday, August 4th. Guggenheim restated a "buy" rating and set a $50.00 target price on shares of Twist Bioscience in a research report on Tuesday, May 6th. Robert W. Baird lowered their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. The Goldman Sachs Group lowered their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Finally, Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Twist Bioscience presently has an average rating of "Moderate Buy" and a consensus target price of $49.40.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,678 shares of the firm's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $35.76, for a total value of $60,005.28. Following the completion of the sale, the chief executive officer owned 645,782 shares of the company's stock, valued at approximately $23,093,164.32. This trade represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Adam Laponis sold 2,449 shares of the firm's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the sale, the chief financial officer directly owned 103,569 shares of the company's stock, valued at approximately $3,951,157.35. This trade represents a 2.31% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 6,089 shares of company stock valued at $217,117. 3.01% of the stock is owned by corporate insiders.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST traded down $0.39 during mid-day trading on Thursday, hitting $26.06. 152,400 shares of the company were exchanged, compared to its average volume of 1,190,887. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The stock has a 50 day simple moving average of $33.78 and a 200-day simple moving average of $36.75. Twist Bioscience Corporation has a 1-year low of $24.28 and a 1-year high of $55.33. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -17.95 and a beta of 2.36.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The firm had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.